









Markets
/
Stocks
/
nasdaq-ptgx
/

Protagonist Therapeutics Inc

PTGX

65.140USD

-2.280-3.38%

Close 09/29, 16:00（ET）Quotes delayed by 15 min

4.03BMarket Cap

10.01P/E TTM



Protagonist Therapeutics Inc

65.140

-2.280-3.38%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Company

Financials

Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Protagonist Therapeutics Inc

Currency: USD Updated: 2025-09-29

Key Insights

The company's fundamentals are relatively very healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. The company is performing well in the stock market, with strong fundamentals and technicals supporting the current trend. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Protagonist Therapeutics Inc's Score

Industry at a Glance

Industry Ranking

22 / 505

Overall Ranking

89 / 4714

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 13 analysts

Buy

Current Rating

70.091

Target Price

+3.96%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Protagonist Therapeutics Inc Highlights

StrengthsRisks

Protagonist Therapeutics, Inc. is a biopharmaceutical company. The Company uses its peptide-based chemical entities rusfertide and JNJ-2113 in different stages of development, all derived from its proprietary discovery technology platform. The Company’s clinical programs fall into two categories of diseases: hematology and blood disorders, and inflammatory and immunomodulatory diseases. Its lead clinical asset, rusfertide (PTG-300), is an injectable hepcidin mimetic in development for the potential treatment of polycythemia vera (PV) and other blood disorders. The Company’s Interleukin-23 receptor (IL-23R) antagonist compound JNJ-2113 is an orally delivered investigational drug that is designed to block biological pathways targeted by marketed injectable antibody drugs. Its PN-943 is a wholly owned investigational orally delivered gut-restricted alpha 4 beta 7 (α4β7) specific integrin antagonist for inflammatory bowel disease (IBD).

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 1534.37% year-on-year.

Turnaround to Profit

The company's performance has turned profitable, with the latest annual net income of USD .

Overvalued

The company’s latest PE is 77.34, at a high 3-year percentile range.

Institutional Selling

The latest institutional holdings are 68.00M shares, decreasing 12.76% quarter-over-quarter.

Held by John Hussman

Star Investor John Hussman holds 31.50K shares of this stock.

Financial Health

Currency: USD Updated: 2025-09-29

The company's current financial score is 8.05, which is higher than the Biotechnology & Medical Research industry's average of 6.92. Its financial status is robust, and its operating efficiency is high. Its latest quarterly revenue reached 5.55M, representing a year-over-year increase of 33.09%, while its net profit experienced a year-over-year increase of 13.57%.

Score

Industry at a Glance

Previous score

8.05

Change



Financials

10.00

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

7.58

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

5.42

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.23

Key Metrics

Free cash flow

No Data

Protagonist Therapeutics Inc's Company Valuation

Currency: USD Updated: 2025-09-29

The company’s current valuation score is 4.19, which is lower than the Biotechnology & Medical Research industry's average of 6.98. Its current P/E ratio is 77.34, which is 3.50% below the recent high of 80.04 and 129.89% above the recent low of -23.11.

Score

Industry at a Glance

Previous score

4.19

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 22/505

No Data

Earnings Forecast

Currency: USD Updated: 2025-09-29

The company’s current earnings forecast score is 8.50, which is higher than the Biotechnology & Medical Research industry's average of 8.03. The average price target for Protagonist Therapeutics Inc is 72.00, with a high of 82.00 and a low of 47.00.

Score

Industry at a Glance

Previous score

8.50

Change

Support & Resistance

No Data

Analyst Rating

Based on 13 analysts

Buy

Current Rating

70.091

Target Price

+3.96%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

554

Total

Median

Average

Company name

Ratings

Analysts

Protagonist Therapeutics Inc

PTGX

CRISPR Therapeutics AG

CRSP

Exact Sciences Corp

EXAS

Ionis Pharmaceuticals Inc

IONS

IQVIA Holdings Inc

IQV

argenx SE

ARGX

...

111

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-09-29

The company’s current price momentum score is 9.36, which is higher than the Biotechnology & Medical Research industry's average of 6.76. Sideways: Currently, the stock price is trading between the resistance level at 70.77 and the support level at 57.01, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

9.67

Change

-0.31

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(3)

Neutral(2)

Buy(2)

Indicators

Value

Direction

MACD(12,26,9)

1.023

Buy

RSI(14)

61.990

Neutral

STOCH(KDJ)(9,3,3)

77.657

Sell

ATR(14)

2.381

High Vlolatility

CCI(14)

88.247

Neutral

Williams %R

28.032

Buy

TRIX(12,20)

0.564

Sell

StochRSI(14)

0.000

Sell

Moving Average

Sell(1)

Neutral(0)

Buy(5)

Indicators

Value

Direction

MA5

65.654

Sell

MA10

63.493

Buy

MA20

61.061

Buy

MA50

57.650

Buy

MA100

54.260

Buy

MA200

48.314

Buy

Institutional Confidence

Currency: USD Updated: 2025-09-29

The company’s current institutional recognition score is 10.00, which is higher than the Biotechnology & Medical Research industry's average of 5.97. The latest institutional shareholding proportion is 109.30%, representing a quarter-over-quarter increase of 0.73%. The largest institutional shareholder is The Vanguard, holding a total of 4.35M shares, representing 6.99% of shares outstanding, with 1.07% decrease in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

BlackRock Institutional Trust Company, N.A.

8.60M

-1.86%

Farallon Capital Management, L.L.C.

6.11M

+2.98%

RTW Investments L.P.

5.72M

+4.02%

The Vanguard Group, Inc.

Star Investors

4.27M

+1.36%

Deep Track Capital LP

3.25M

+8.33%

BVF Partners L.P.

3.21M

+24.70%

State Street Global Advisors (US)

2.71M

-18.75%

Johnson & Johnson Innovation-JJDC, Inc.

2.45M

Geode Capital Management, L.L.C.

1.42M

+3.38%

Risk Assessment

Currency: USD Updated: 2025-09-29

The company’s current risk assessment score is 7.08, which is higher than the Biotechnology & Medical Research industry's average of 3.49. The company's beta value is 2.23. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.